^
    Back
    Association details:
    Biomarker:ESR1 mutation
    Cancer:Breast Cancer
    Drug:camizestrant (AZD9833) (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

    Excerpt:
    ...- Have an ESR1 mutation in their cancer;...
    Trial ID:
    SERENA-6
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2022
    Title:

    P3-07-13 The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

    Published date:
    11/22/2022
    Excerpt:
    Interestingly, the clinical activity of camizestrant was higher in heavily pretreated patients with metastatic breast cancer with ESR1m tumors compared to those with no detectable mutation (ESR1m not detected). At a camizestrant dose of 75 mg, median progression-free survival was 8.3 months (maturity 12/15) in patients with ESR1m tumors...These data demonstrate the activity of camizestrant in patients with ESR1m tumors.